Levonorgestrel and Ethinyl Estradiol Tablets USP

SECTION 2: Hazards identification

Fire and Explosion Expected to be non-combustible. Health Combination oral contraceptives should not be used in women with any of the following conditions: Thrombophlebitis or thromboembolic disorders. A history of deep-vein thrombophlebitis or thromboembolic disorders. Cerebrovascular or coronary artery disease (current or past history). Valvular heart disease with thrombogenic complications. Thrombogenic rhythm disorders. Hereditary or acquired thrombophilias. Major surgery with prolonged immobilization. Diabetes with vascular involvement. Headaches with focal neurological symptoms. Uncontrolled hypertension. Known or suspected carcinoma of the breast or personal history of breast cancer Carcinoma of the endometrium or other known or suspected estrogen-dependent neoplasia. Undiagnosed abnormal genital bleeding. Cholestatic jaundice of pregnancy or jaundice with prior pill use. Hepatic adenomas or carcinomas, or active liver disease Known or suspected pregnancy. Hypersensitivity to any of the components of levonorgestrel and ethinyl estradiol tablets. Are receiving Hepatitis C drug combinations containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir, due to the potential for ALT elevations.

Environmental hazards

No information is available about the potential of this product to produce adverse environmental effects.